Has Aman Garsa, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,205 in general payments to Aman Garsa, MD across 512 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aman Garsa, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aman Garsa, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aman Garsa, MD

Hematology & Oncology · Dallas, TXNPI 1821296047

Payments from drug & device makers

$9,205in general payments, 2019–2025

Across 512 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Merck$623
E.r. Squibb & Sons, L.L.C.$555
Pfizer$489
Amgen$417
Novartis$398
plus $6K from 54 others

What the payments were for

Food & beverage$8,84596%
Education$3604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	57	$1,021
Merck	40	$623
E.r. Squibb & Sons, L.L.C.	37	$555
Pfizer	31	$489
Amgen	21	$417
Novartis	23	$398
Daiichi Sankyo Inc.	13	$328
Gilead(2 entities)	17	$319
Johnson & Johnson	15	$280
Pharmacyclics LLC, An Abbvie Company	15	$275
Genentech USA, Inc.	19	$274
Incyte Corporation	14	$261
Lilly USA, LLC	13	$247
Takeda Pharmaceuticals U.S.A., Inc.	13	$241
Sanofi	13	$241
Seagen Inc.	11	$223
Eisai Inc.	12	$223
Bristol Myers Squibb	10	$215
Rigel Pharmaceuticals, Inc.	11	$189
Regeneron Healthcare Solutions, Inc.	9	$185
Array Biopharma Inc	9	$180
Bayer	8	$144
GSK	7	$140
Tempus AI, Inc	5	$134
Taiho Oncology, Inc.	6	$121
AbbVie	6	$107
Puma Biotechnology, Inc.	7	$98
Boehringer Ingelheim	5	$84
ADC Therapeutics America, Inc.	4	$78
Pharmacosmos Therapeutics Inc.	5	$72
Exelixis Inc.	4	$72
Blueprint Medicines Corporation	3	$70
Myriad Genetic Laboratories, Inc.	4	$69
Sobi, Inc	3	$67
EMD Serono, Inc.	4	$63
Genmab U.S., Inc.	2	$52
Karyopharm Therapeutics Inc.	3	$42
AVEO Pharmaceuticals, Inc.	2	$42
Astellas Pharma US Inc	2	$39
Sirtex Medical Inc	2	$35
Beone Medicines USA, Inc.	1	$33
Deciphera Pharmaceuticals Inc.	1	$33
Tesaro, Inc.	2	$28
Foundation Medicine, Inc.	2	$28
Dova Pharmaceuticals	2	$26
Syndax Pharmaceuticals, Inc.	1	$25
Vyera Pharmaceuticals, LLC	2	$25
G1 Therapeutics, Inc.	1	$24
Sumitomo Pharma America, Inc.	1	$24
Abbott	1	$24
Servier Pharmaceuticals LLC	1	$23
Shield Therapeutics Inc	1	$23
Fortovia Therapeutics, Inc.	2	$23
Geron Corporation	1	$22
Sun Pharmaceutical Industries Inc.	1	$20
Sanofi-aventis U.S. LLC	1	$19
Springworks Therapeutics, Inc.	1	$18
Mirati Therapeutics, Inc.	1	$18
Coherus Oncology, Inc.	1	$17
Beigene USA, Inc.	1	$15

How this compares

$9,205 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$234,488

Medicare patients

171

Services billed

9,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Dallas

Prapti PatelDallas$10.3M
Farrukh AwanDallas$8.4M
Elizabeth MaherDallas$5.5M
Kevin CourtneyDallas$4.8M
Jaime BrugarolasDallas$2.8M
Syed KazmiDallas$2.5M
Elias JabbourHouston$264.1M
Luhua WangHouston$79.6M
Courtney DinardoHouston$74M
Jorge Cortes-FrancoHouston$59.4M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →